Literature DB >> 27790370

Tissue-engineered 3D cancer-in-bone modeling: silk and PUR protocols.

Ushashi Dadwal1, Carolyne Falank2, Heather Fairfield2, Sarah Linehan2, Clifford J Rosen3, David L Kaplan4, Julie Sterling5, Michaela R Reagan3.   

Abstract

Cancers that metastasize or grow in the bone marrow are typically considered incurable and cause extensive damage to the bone and bone marrow. The bone is a complex, dynamic, three-dimensional (3D) environment composed of a plethora of cells that may contribute to, or constrain, the growth of tumor cells and development of bone disease. The development of safe and effective drugs is currently hampered by pre-clinical two-dimensional (2D) models whose poor predictive power does not accurately predict the success or failure of therapeutics. These inadequate models often result in drugs proceeding through extensive pre-clinical studies only to fail clinically. Consistently, 3D co-culture systems prove superior to 2D mono-cultures in modeling in vivo cell phenotypes, disease progression and response to therapeutics. As a complex, multicellular, multidimensional bone microenvironment, 3D models allow for more accurate predictions of tumor growth, cell-cell and cell-matrix interactions, and resulting therapeutic responses. In this review we will discuss various 3D models available and describe step-by-step protocols for two of the most well-established 3D culture models for studying tumor-induced bone disease.

Entities:  

Year:  2016        PMID: 27790370      PMCID: PMC5070496          DOI: 10.1038/bonekey.2016.75

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  59 in total

1.  Novel approach to fabricate keratin sponge scaffolds with controlled pore size and porosity.

Authors:  Kazunori Katoh; Toshizumi Tanabe; Kiyoshi Yamauchi
Journal:  Biomaterials       Date:  2004-08       Impact factor: 12.479

2.  Photopolymerizable chitosan-collagen hydrogels for bone tissue engineering.

Authors:  Christopher Arakawa; Ronald Ng; Steven Tan; Soyon Kim; Benjamin Wu; Min Lee
Journal:  J Tissue Eng Regen Med       Date:  2014-04-28       Impact factor: 3.963

3.  The development of a tissue-engineered tracheobronchial epithelial model using a bilayered collagen-hyaluronate scaffold.

Authors:  Cian O'Leary; Brenton Cavanagh; Ronald E Unger; C James Kirkpatrick; Shirley O'Dea; Fergal J O'Brien; Sally-Ann Cryan
Journal:  Biomaterials       Date:  2016-02-01       Impact factor: 12.479

4.  One size does not fit all: developing a cell-specific niche for in vitro study of cell behavior.

Authors:  Milos Marinkovic; Travis J Block; Rubie Rakian; Qihong Li; Exing Wang; Matthew A Reilly; David D Dean; Xiao-Dong Chen
Journal:  Matrix Biol       Date:  2016-01-15       Impact factor: 11.583

5.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 6.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 7.  Biomechanical forces in the skeleton and their relevance to bone metastasis: biology and engineering considerations.

Authors:  Maureen E Lynch; Claudia Fischbach
Journal:  Adv Drug Deliv Rev       Date:  2014-08-29       Impact factor: 15.470

8.  Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells.

Authors:  Nazanin S Ruppender; Alyssa R Merkel; T John Martin; Gregory R Mundy; Julie A Sterling; Scott A Guelcher
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

9.  In vitro model of vascularized bone: synergizing vascular development and osteogenesis.

Authors:  Cristina Correia; Warren L Grayson; Miri Park; Daphne Hutton; Bin Zhou; X Edward Guo; Laura Niklason; Rui A Sousa; Rui L Reis; Gordana Vunjak-Novakovic
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

10.  Differential matrix rigidity response in breast cancer cell lines correlates with the tissue tropism.

Authors:  Ana Kostic; Christopher D Lynch; Michael P Sheetz
Journal:  PLoS One       Date:  2009-07-23       Impact factor: 3.240

View more
  7 in total

1.  Development of a 3D bone marrow adipose tissue model.

Authors:  Heather Fairfield; Carolyne Falank; Mariah Farrell; Calvin Vary; Joshua M Boucher; Heather Driscoll; Lucy Liaw; Clifford J Rosen; Michaela R Reagan
Journal:  Bone       Date:  2018-01-31       Impact factor: 4.398

Review 2.  A perspective on malignancy in the marrow.

Authors:  Michaela R Reagan; Jane B Lian; Clifford J Rosen; Gary S Stein
Journal:  J Cell Physiol       Date:  2017-05-16       Impact factor: 6.384

Review 3.  Characterisation of Selected Materials in Medical Applications.

Authors:  Kacper Kroczek; Paweł Turek; Damian Mazur; Jacek Szczygielski; Damian Filip; Robert Brodowski; Krzysztof Balawender; Łukasz Przeszłowski; Bogumił Lewandowski; Stanisław Orkisz; Artur Mazur; Grzegorz Budzik; Józef Cebulski; Mariusz Oleksy
Journal:  Polymers (Basel)       Date:  2022-04-09       Impact factor: 4.967

4.  3d Tissue Engineered In Vitro Models Of Cancer In Bone.

Authors:  Anna M Sitarski; Heather Fairfield; Carolyne Falank; Michaela R Reagan
Journal:  ACS Biomater Sci Eng       Date:  2017-06-09

Review 5.  Animal models for bone tissue engineering and modelling disease.

Authors:  Jacqui Anne McGovern; Michelle Griffin; Dietmar Werner Hutmacher
Journal:  Dis Model Mech       Date:  2018-04-23       Impact factor: 5.758

Review 6.  Critical Assessment of In Vitro and In Vivo Models to Study Marrow Adipose Tissue.

Authors:  Michaela R Reagan
Journal:  Curr Osteoporos Rep       Date:  2020-04       Impact factor: 5.096

7.  In vitro tissue-engineered adipose constructs for modeling disease.

Authors:  Connor S Murphy; Lucy Liaw; Michaela R Reagan
Journal:  BMC Biomed Eng       Date:  2019-10-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.